2004
Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916
Crawford E, Pauler D, Tangen C, Hussain M, Small E, Taplin M, Burch P, Greene G, Lara P, Petrylak D. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. Journal Of Clinical Oncology 2004, 22: 4505-4505. DOI: 10.1200/jco.2004.22.14_suppl.4505.Peer-Reviewed Original ResearchThree-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916
Crawford E, Pauler D, Tangen C, Hussain M, Small E, Taplin M, Burch P, Greene G, Lara P, Petrylak D. Three-month change in PSA as a surrogate endpoint for mortality in advanced hormone-refractory prostate cancer (HRPC): Data from Southwest Oncology Group Study S9916. Journal Of Clinical Oncology 2004, 22: 4505-4505. DOI: 10.1200/jco.2004.22.90140.4505.Peer-Reviewed Original Research
1999
Refractory disease, new horizons and patient–physician relationships
Glode L, Petrylak D. Refractory disease, new horizons and patient–physician relationships. Prostate Cancer And Prostatic Diseases 1999, 2: 19-20. PMID: 12496852, DOI: 10.1038/sj.pcan.4500272.Peer-Reviewed Original ResearchMore cost-effective careRole of chemotherapyDisease-free intervalPhase III trialsUse of PSACost-effective careProstate cancer cellsPatient-physician relationshipAdvanced diseasePain controlIII trialsRefractory diseaseNumerous new targetsFree intervalProstate cancerTreatment endpointSurrogate endpointsBiologic understandingCancer cellsDisease targetsEndpointNew targetsGrowth factor interactionsChemotherapyDisease
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply